Early promise for Progenics' MAb HIV entry inhibitor
This article was originally published in Scrip
Progenics Pharmaceuticalshas presented positive interim results from two separate Phase II trials of subcutaneous and intravenous formulations of PRO 140 – a novel humanised monoclonal antibody CCR5 antagonist – in treatment-naive HIV patients. The data were presented at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.